Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell P Fink

Showing results (1-10 of 145) with videos related to

Pageof 15
Sort By:
Critical Care Medicine|February 19, 2014
Acute pancreatitis: a lame duct problem?*Mitchell P Fink
Critical Care Medicine|January 18, 2012
Matrix metalloproteinase-8 as a potential drug target for the therapy of sepsisMitchell P Fink
Critical Care Medicine|September 9, 2005
What do insulin, estrogen, valproic acid, and TDZD-8 have in common?Mitchell P Fink
Novartis Foundation Symposium|March 27, 2007
Ethyl pyruvate: a novel treatment for sepsisMitchell P Fink
Intensive Care Medicine|March 22, 2002
Clinical tests of gastrointestinal permeability that rely on the urinary recovery of enterally administered probes can yield invalid results in critically ill patientsMitchell P Fink
Critical Care Clinics|March 26, 2002
Cytopathic hypoxia. Is oxygen use impaired in sepsis as a result of an acquired intrinsic derangement in cellular respiration?Mitchell P Fink
Kidney International|October 2, 2008
Animal models of sepsis and its complicationsMitchell P Fink
Critical Care (London, England)|July 17, 2014
HMGB1 as a drug target in staphylococcal pneumoniaMitchell P Fink
Journal of Leukocyte Biology|March 3, 2010
Editorial: Lepromatous leprosy, lipids, and lessons in immunology: what we can learn by using modern methods to study an ancient diseaseMitchell P Fink
Critical Care Medicine|February 6, 2004
Peroxisome proliferator-activated receptor-gamma ligands: a pluripotent class of pharmacological agents that may prove to be useful for adjuvant treatment of sepsis and multiple organ dysfunction syndromeMitchell P Fink
Pageof 15

Showing results (1-10 of 145) with videos related to

Sort By:
Pageof 15
Critical Care Medicine|February 19, 2014
Acute pancreatitis: a lame duct problem?*Mitchell P Fink
Critical Care Medicine|January 18, 2012
Matrix metalloproteinase-8 as a potential drug target for the therapy of sepsisMitchell P Fink
Critical Care Medicine|September 9, 2005
What do insulin, estrogen, valproic acid, and TDZD-8 have in common?Mitchell P Fink
Novartis Foundation Symposium|March 27, 2007
Ethyl pyruvate: a novel treatment for sepsisMitchell P Fink
Intensive Care Medicine|March 22, 2002
Clinical tests of gastrointestinal permeability that rely on the urinary recovery of enterally administered probes can yield invalid results in critically ill patientsMitchell P Fink
Critical Care Clinics|March 26, 2002
Cytopathic hypoxia. Is oxygen use impaired in sepsis as a result of an acquired intrinsic derangement in cellular respiration?Mitchell P Fink
Kidney International|October 2, 2008
Animal models of sepsis and its complicationsMitchell P Fink
Critical Care (London, England)|July 17, 2014
HMGB1 as a drug target in staphylococcal pneumoniaMitchell P Fink
Journal of Leukocyte Biology|March 3, 2010
Editorial: Lepromatous leprosy, lipids, and lessons in immunology: what we can learn by using modern methods to study an ancient diseaseMitchell P Fink
Critical Care Medicine|February 6, 2004
Peroxisome proliferator-activated receptor-gamma ligands: a pluripotent class of pharmacological agents that may prove to be useful for adjuvant treatment of sepsis and multiple organ dysfunction syndromeMitchell P Fink
Pageof 15